Raven will also supply a related antibody library to assess the development of diagnostic tools for cancer prognosis and treatment.
Raven biotechnologies and a researcher at Emory University Medical School entered a cancer stem cell research collaboration. With the focus on prostate cancer, the partners will also assess the development of diagnostic and prognostic tests.
Leland W.K. Chung, Ph.D., director of the molecular urology and therapeutics program at the Emory University Medical School’s department of urology will have access to Raven’s prostate cancer stem cells. Dr. Chung and the company will examine prostate cancer biology, disease progression, and subsequent metastasis.
Raven will also provide Emory with a library of antibodies targeting cancer stem cells to study their use as prognostic devices and to monitor treatment.